A Canarypox Vector Expressing Cytomegalovirus (CMV) Glycoprotein B Primes for Antibody Responses to a Live Attenuated CMV Vaccine (Towne) | Zendy

Stuart P. Adler | Zendy; Stanley A. Plotkin | Zendy; Éva Gönczöl | Zendy; M. Cadoz | Zendy; Claude Méric | Zendy; Jian Ben Wang | Zendy; P. Dellamonica | Zendy; Al M. Best | Zendy; John M. Zahradnik | Zendy; S Pincus | Zendy; Klára Berencsi | Zendy; William I. Cox | Zendy; Zsófia Gyulai | Zendy

Open Access

A Canarypox Vector Expressing Cytomegalovirus (CMV) Glycoprotein B Primes for Antibody Responses to a Live Attenuated CMV Vaccine (Towne)

Author(s) -

Stuart P. Adler,

Stanley A. Plotkin,

Éva Gönczöl,

M. Cadoz,

Claude Méric,

Jian Ben Wang,

P. Dellamonica,

Al M. Best,

John M. Zahradnik,

S Pincus,

Klára Berencsi,

William I. Cox,

Zsófia Gyulai

Publication year - 1999

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/314951

Subject(s) - virology , antibody , human cytomegalovirus , neutralizing antibody , immunology , cytomegalovirus , medicine , biology , herpesviridae , virus , viral disease

To develop a vaccine against cytomegalovirus (CMV), a canarypox virus (ALVAC) expressing CMV glycoprotein (gB) was evaluated alone or in combination with a live, attenuated CMV vaccine (Towne). Three doses of 106.5 TCID50 of ALVAC-CMV(gB) induced very low neutralizing or ELISA antibodies in most seronegative adults. However, to determine whether ALVAC-CMV(gB) could prime for antibody responses, 20 seronegative adults randomly received either 106.8 TCID50 of ALVAC-CMV(gB) or 106.8 TCID50 of ALVAC-RG, expressing the rabies glycoprotein, administered at 0 and 1 month, with all subjects receiving a dose of 103.5 pfu of the Towne vaccine at 90 days. For subjects primed with ALVAC-CMV(gB), neutralizing titers and ELISA antibodies to CMV(gB) developed sooner, were much higher, and persisted longer than for subjects primed with ALVAC-RG. All vaccines were well tolerated. These results demonstrate that ALVAC-CMV(gB) primes the immune system and suggest a combined-vaccine strategy to induce potentially protective levels of neutralizing antibodies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research